Similar α-Synuclein staining in the colon mucosa in patients with Parkinson's disease and controls

Movement Disorders

Volumn 31, Issue 10, 2016, Pages 1567-1570

  Antunes, Laurent ^a   Frasquilho, Sonia ^a   Ostaszewski, Marek ^a,b   Weber, Jos ^c   Longhino, Laura ^b   Antony, Paul ^b   Baumuratov, Aidos ^b   Buttini, Manuel ^b   Shannon, Kathleen M ^d   Balling, Rudi ^b   Diederich, Nico J ^b  

^a INTEGRATED BIOBANK OF LUXEMBOURG   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^d RUSH MEDICAL COLLEGE   (United States)

Author keywords

alpha synuclein; biomarker; colon; mucosa; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA; PRAMIPEXOLE;

AGED; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; STAINING; SUBMUCOSA;

EID: 84991226015     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26702     Document Type: Article

References (20)

1. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003;110:517–536.
2. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709–715.
3. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE 2011;6(12):e28032. doi: 10.1371/journal.pone.0028032
4. Hilton D, Stephens M, Kirk L, et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol 2014;127:235–241.
5. Beach TG, Adler CH, Sue LI, et al. Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689–702.
6. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience 2008;153:733–750.
7. Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29:1010–1018.
8. Gray MT, Munoz DG, Gray DA, Schlossmacher MG, Woulfe JM. Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord 2014;29:991–998.
9. Visanji NP, Marras C, Kern DS, et al. Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015;84:609–616.
10. Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015;14:855–866.
11. Diederich NJ, Pieri V, Hipp G, et al. Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study. Mov Disord 2010;25:882–887.
12. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;15:2649–2653.
13. Böttner M, Zorenkov D, Hellwig I, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 2012;48:474–480.
14. Sprenger FS, Stefanova N, Gelpi E. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behaviour disorder. Neurology 2015;85:1761–1768.
15. Pouclet H, Lebouvier T, Coron E, et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. Neurobiol Dis 2012;45:305–309.
16. Kellie JF, Higgs RE, Ryder JW, et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep 2014;4:5797. doi: 0.1038/srep05797
17. Chung SJ, Kim J, Lee HJ, et al. Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker. Mov Disord 2016;31:241–249.
18. Visanji NP, Lang AE, Hazrai LN. Colonic mucosal alpha synuclein lacks specificity as a biomarker for Parkinson disease. Author response. Neurology 2015;85:834–835.
19. Koehler NK, Stransky E, Meyer M, et al. Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS ONE 2015;10(4):e0123444.
20. Xiang W, Menges S, Schlachetzki JC, et al. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity. Mol Neurodegener 2015;10:8. doi: 10.1186/s13024-015-0004-0